

Cipla Health targets 3x growth in 5 years, bets big on beauty and wellness
Mint.The growth ambition comes as India’s premium personal care and wellness market intensifies, drawing aggressive FMCG majors, venture-backed startups and global brands. Cipla Health is betting that its pharmaceutical lineage and scientific credibility can help it scale brands into large consumer franchises.“We don't have as many large consumer health brands in India at the moment,” Puri said.
“We believe that we have cracked a thesis where we are now onto something which can become very very large. So we are very excited about the journey,” he added.Cipla Health’s top brands—Nicotex, Cofsils, Prolyte ORS and Omnigel—each generate ₹200-400 crore annually, according to Puri.
Nicotex and Omnigel are also the market leaders in their respective segments, according to him.In FY25, Cipla Health posted revenue of ₹1,220 crore, up 16% year-on-year, and net profit of ₹119 crore, a 39% increase from the previous year.“We are close to reaching the ₹1,500-600 crore target in the near future”, he added.The company is now entering high-growth segments. In October 2025, Cipla Health entered the sexual wellness category with Unfold condoms.The Indian condom market is estimated at $290–320 million, according to Global Market Insights.
Mankind Pharma’s Manforce is the largest condom brand in the country, followed by Reckitt Benckiser’s Durex. Manforce held 29% market share in FY25 and generated ₹538 crore in revenue that year, according to its annual report.Puri signalled that condoms are only the starting point.“Condoms were an entry point.
We are now in a lot of detail in looking at various other needs for consumers,” Puri said. “It is still a fairly unanswered sector because there's a need for a lot of responsible products in the
. Read on livemint.com